Bokf Na Buys 2,844 Shares of Royalty Pharma plc (NASDAQ:RPRX)

Bokf Na raised its stake in Royalty Pharma plc (NASDAQ:RPRX) by 18.4% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 18,280 shares of the biopharmaceutical company’s stock after purchasing an additional 2,844 shares during the quarter. Bokf Na’s holdings in Royalty Pharma were worth $547,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently bought and sold shares of the stock. Fidelis Capital Partners LLC bought a new position in shares of Royalty Pharma during the 1st quarter worth approximately $46,000. Allworth Financial LP lifted its holdings in Royalty Pharma by 76.7% during the 4th quarter. Allworth Financial LP now owns 1,684 shares of the biopharmaceutical company’s stock worth $47,000 after purchasing an additional 731 shares during the last quarter. GAMMA Investing LLC lifted its holdings in Royalty Pharma by 172.5% during the 1st quarter. GAMMA Investing LLC now owns 1,638 shares of the biopharmaceutical company’s stock worth $50,000 after purchasing an additional 1,037 shares during the last quarter. EverSource Wealth Advisors LLC lifted its holdings in Royalty Pharma by 79.8% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,807 shares of the biopharmaceutical company’s stock worth $51,000 after purchasing an additional 802 shares during the last quarter. Finally, Lindbrook Capital LLC lifted its holdings in Royalty Pharma by 485.2% during the 4th quarter. Lindbrook Capital LLC now owns 2,411 shares of the biopharmaceutical company’s stock worth $68,000 after purchasing an additional 1,999 shares during the last quarter. 54.35% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several analysts recently weighed in on RPRX shares. StockNews.com cut Royalty Pharma from a “buy” rating to a “hold” rating in a report on Friday, May 10th. Bank of America dropped their price objective on Royalty Pharma from $40.00 to $38.00 and set a “buy” rating for the company in a report on Friday, April 12th. UBS Group cut Royalty Pharma from a “buy” rating to a “neutral” rating and set a $28.00 price objective for the company. in a report on Monday, June 3rd. Finally, Morgan Stanley boosted their price target on Royalty Pharma from $48.00 to $51.00 and gave the stock an “overweight” rating in a report on Thursday, July 11th. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $41.80.

Royalty Pharma Price Performance

RPRX stock traded down $0.07 during midday trading on Monday, reaching $28.72. 212,580 shares of the stock were exchanged, compared to its average volume of 2,648,125. The stock has a market capitalization of $17.16 billion, a PE ratio of 21.49, a P/E/G ratio of 3.78 and a beta of 0.46. Royalty Pharma plc has a 52 week low of $25.20 and a 52 week high of $31.66. The company has a debt-to-equity ratio of 0.62, a current ratio of 12.52 and a quick ratio of 12.52. The company has a fifty day moving average price of $26.98 and a 200 day moving average price of $28.39.

Royalty Pharma (NASDAQ:RPRX) last released its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported $0.98 EPS for the quarter, beating analysts’ consensus estimates of $0.96 by $0.02. The firm had revenue of $568.00 million for the quarter, compared to analyst estimates of $671.45 million. Royalty Pharma had a return on equity of 22.94% and a net margin of 35.70%. During the same quarter in the previous year, the company posted $1.60 EPS. As a group, analysts expect that Royalty Pharma plc will post 4.01 EPS for the current fiscal year.

Royalty Pharma Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 13th. Stockholders of record on Friday, August 16th will be paid a $0.21 dividend. This represents a $0.84 dividend on an annualized basis and a dividend yield of 2.92%. The ex-dividend date is Friday, August 16th. Royalty Pharma’s dividend payout ratio is 62.69%.

Royalty Pharma Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.